[go: up one dir, main page]

HRP20220127T1 - Supstituirani spoj piperidina i njegova uporaba - Google Patents

Supstituirani spoj piperidina i njegova uporaba Download PDF

Info

Publication number
HRP20220127T1
HRP20220127T1 HRP20220127TT HRP20220127T HRP20220127T1 HR P20220127 T1 HRP20220127 T1 HR P20220127T1 HR P20220127T T HRP20220127T T HR P20220127TT HR P20220127 T HRP20220127 T HR P20220127T HR P20220127 T1 HRP20220127 T1 HR P20220127T1
Authority
HR
Croatia
Prior art keywords
group
optionally substituted
alkyl
substituents selected
groups
Prior art date
Application number
HRP20220127TT
Other languages
English (en)
Inventor
Tatsuhiko Fujimoto
Kentaro Rikimaru
Koichiro Fukuda
Hiromichi Sugimoto
Takahiro Matsumoto
Norihito Tokunaga
Mariko Hirozane
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of HRP20220127T1 publication Critical patent/HRP20220127T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (9)

1. Spoj, naznačen time, da je predstavljen formulom: [image] u kojoj R1 je (1) atom vodika, (2) C1-6 alkil-karbonil skupina koja je opcionalno supstituirana s 1 do 7 supstituenata koji se biraju od sljedećih: (i) atom halogena, (ii) cijano skupina, (iii) hidroksi skupina, (iv) C3-10 cikloalkil skupina, (v) C1-6 alkoksi skupina, (vi) C6-14 aril skupina, (vii) C6-14 ariloksi skupina, (viii) pirazolil skupina, tiazolil skupina, pirimidinil skupina ili piridazinil skupina, od kojih je svaka opcionalno supstituirana s okso skupinom, (ix) pirazoliloksi skupina koja je opcionalno supstituirana s 1 do 3 C1-6 alkil skupine, (x) C1-6 alkil-karbonil skupina, (xi) C1-6 alkoksi-karbonil skupina, (xii) C1-6 alkil-karboniloksi skupina, (xiii) C1-6 alkilsulfonil skupina, (xiv) mono- ili di-C1-6 alkilamino skupina, (xv) C1-6 alkil-karbonilamino skupina i (xvi) (C1-6 alkil)(C1-6 alkil-karbonil) amino skupina, (3) C3-10 cikloalkil-karbonil skupina koja je opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od atoma halogena, cijano skupine, hidroksi skupine, okso skupine i C1-6 alkil skupine, (4) C1-6 alkoksi-karbonil skupina koja je opcionalno supstituirana s 1 do 6 supstituenata koji se biraju od deuterija, atoma halogena i C6-14 aril skupine, (5) C3-10 cikloalkiloksi-karbonil skupina koja je opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od C1-6 alkil skupine, (6) C6-14 aril-karbonil skupina koja je opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od atoma halogena i C6-14 aril skupine, (7) C6-14 ariloksi-karbonil skupina, (8) furilkarbonil skupina, tienilkarbonil skupina, pirazolilkarbonil skupina, izoksazolilkarbonil skupina ili piridilkarbonil skupina, od kojih je svaka opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od C1-6 alkil skupine, (9) azetidinilkarbonil skupina, oksetanilkarbonil skupina, pirolidinilkarbonil skupina, tetrahidrofuranilkarbonil skupina, tetrahidropiranilkarbonil skupina ili morfolinilkarbonil skupina, od kojih je svaka opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od okso skupine, C1-6 alkil-karbonil skupine, C1-6 alkoksi-karbonil skupine i C1-6 alkilsulfonil skupine, (10) mono- ili di-C1-6 alkil-karbamoil skupina koja je opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od atoma halogena, cijano skupine, hidroksi skupine i C1-6 alkoksi skupine, (11) mono- ili di-C3-10 cikloalkil-karbamoil skupina, (12) mono- ili di-C6-14 aril-karbamoil skupina, (13) C1-6 alkilsulfonil skupina, (14) C3-10 cikloalkilsulfonil skupina, (15) C6-14 arilsulfonil skupina koja je opcionalno supstituirana s 1 do 3 atoma halogena, (16) tienilsulfonil skupina, pirazolilsulfonil skupina, imidazolilsulfonil skupina, piridilsulfonil skupina ili dihidrokromenilsulfonil skupina, od kojih je svaka opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od C1-6 alkil skupine, (17) mono- ili di-C1-6 alkil-sulfamoil skupina, ili (18) C1-6 alkil-karbonil-karbonil skupina; R2 je C3-6 cikloalkil skupina, pirolidinil skupina, piperidinil skupina ili dioksanil skupina, od kojih je svaka opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od sljedećih: (1) deuterij, (2) atom halogena, (3) hidroksi skupina, (4) C1-6 alkil skupina koja je opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od atoma halogena i C6-14 aril skupine, (5) C3-10 cikloalkil skupina, (6) C1-6 alkoksi skupina koja je opcionalno supstituirana sa C3-10 cikloalkil skupinom, (7) C6-14 aril skupina koja je opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od atoma halogena, cijano skupine, C1-6 alkil skupine koja je opcionalno supstituirana s 1 do 3 atoma halogena, C1-6 alkoksi skupine koja je opcionalno supstituirana s 1 do 3 atoma halogena i hidroksi skupine, (8) C6-14 ariloksi skupina, (9) tri-C1-6 alkilsililoksi skupina, (10) pirazolil skupina, tiazolil skupina, piridil skupina, pirimidinil skupina, kinazolinil skupina, benzotiazolil skupina ili izokinolinil skupina, od kojih je svaka opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od atoma halogena, C1-6 alkil skupine i C1-6 alkoksi skupine, i (11) C6-14 aril-karbonil skupina; i R3 je C1-6 alkil skupina ili mono- ili di-C1-6 alkilamino skupina, ili njegova sol.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da je predstavljen formulom: [image] u kojoj su R1, R2 i R3 isti kao što su definirani u patentnom zahtjevu 1, ili njegova sol.
3. Spoj prema patentnom zahtjevu 1, naznačen time, da R1 je (1) atom vodika, (2) C1-6 alkil-karbonil skupina koja je opcionalno supstituirana s hidroksi skupinom, (3) ciklopropankarbonil skupina, (4) C1-6 alkoksi-karbonil skupina, ili (5) mono- ili di-C1-6 alkil-karbamoil skupina; R2 je (A) cikloheksil skupina koja je opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od sljedećih: (1) C1-6 alkil skupina, i (2) fenil skupina koja je opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od atoma halogena, C1-6 alkil skupine opcionalno supstituirane s 1 do 3 atoma halogena i C1-6 alkoksi skupine, ili (B) piperidinil skupina koja je opcionalno supstituirana s 1 do 3 pirimidinil skupine; i R3 je C1-6 alkil skupina ili di-C1-6 alkilamino skupina, ili njegova sol.
4. Spoj prema patentnom zahtjevu 1, naznačen time, da R1 je (1) C1-6 alkil-karbonil skupina koja je opcionalno supstituirana s hidroksi skupinom, (2) C1-6 alkoksi-karbonil skupina, ili (3) mono- ili di-C1-6 alkil-karbamoil skupina; R2 je cikloheksil skupina koja je opcionalno supstituirana s 1 do 3 supstituenta koji se biraju od sljedećih: (1) C1-6 alkil skupina, i (2) fenil skupina koja je opcionalno supstituirana s 1 do 3 atoma halogena; i R2 je C1-6 alkil skupina, ili njegova sol.
5. Spoj prema patentnom zahtjevu 1, naznačen time, da je metil (2R,3S)-3-((metilsulfonil)amino)-2-(((cis-4-fenilcikloheksil)oksi)metil)piperidin-1-karboksilat ili njegova sol.
6. Spoj prema patentnom zahtjevu 1, naznačen time, da je N-(2R,3S)-1-glikoloil-2-(((cis-4-(2,3,6-trifluorofenil)cikloheksil)oksi)metil)piperidin-3-il)metansulfonamid ili njegova sol.
7. Spoj prema patentnom zahtjevu 1, naznačen time, da je (2R,3S)-N-etil-2-(((cis-4-izopropilcikloheksil)oksi)metil)-3-((metilsulfonil)amino)piperidin-1-karboksamid ili njegova sol.
8. Lijek, naznačen time, da sadrži spoj prema patentnom zahtjevu 1, ili njegovu sol.
9. Spoj prema patentnom zahtjevu 1 ili njegova sol, naznačen time, da je za uporabu u profilaksi ili liječenju narkolepsije.
HRP20220127TT 2016-02-04 2017-02-01 Supstituirani spoj piperidina i njegova uporaba HRP20220127T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016019834 2016-02-04
PCT/JP2017/003610 WO2017135306A1 (en) 2016-02-04 2017-02-01 Substituted piperidine compound and use thereof
EP17705706.4A EP3411358B1 (en) 2016-02-04 2017-02-01 Substituted piperidine compound and use thereof

Publications (1)

Publication Number Publication Date
HRP20220127T1 true HRP20220127T1 (hr) 2022-04-15

Family

ID=58054473

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20241334TT HRP20241334T1 (hr) 2016-02-04 2017-02-01 Supstituirani piperidinski spoj kao agonist oreksina tipa 2 za liječenje narkolepsije
HRP20220127TT HRP20220127T1 (hr) 2016-02-04 2017-02-01 Supstituirani spoj piperidina i njegova uporaba

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20241334TT HRP20241334T1 (hr) 2016-02-04 2017-02-01 Supstituirani piperidinski spoj kao agonist oreksina tipa 2 za liječenje narkolepsije

Country Status (36)

Country Link
US (6) US10508083B2 (hr)
EP (3) EP4438041A3 (hr)
JP (1) JP6609060B2 (hr)
KR (1) KR102734774B1 (hr)
CN (2) CN114181136A (hr)
AR (1) AR107519A1 (hr)
AU (1) AU2017215021B2 (hr)
BR (1) BR112018015574B1 (hr)
CA (1) CA3013428C (hr)
CL (1) CL2018002099A1 (hr)
CO (1) CO2018008705A2 (hr)
CY (1) CY1125003T1 (hr)
DK (2) DK3984994T3 (hr)
EA (1) EA036166B1 (hr)
EC (1) ECSP18066504A (hr)
ES (2) ES2991028T3 (hr)
FI (1) FI3984994T3 (hr)
HR (2) HRP20241334T1 (hr)
HU (2) HUE057696T2 (hr)
IL (1) IL260835B (hr)
LT (2) LT3984994T (hr)
MA (1) MA43963A (hr)
MX (1) MX382435B (hr)
MY (1) MY186905A (hr)
PH (1) PH12018501666B1 (hr)
PL (2) PL3984994T3 (hr)
PT (2) PT3411358T (hr)
RS (2) RS65984B1 (hr)
SG (1) SG11201806429PA (hr)
SI (2) SI3411358T1 (hr)
TN (1) TN2018000262A1 (hr)
TW (2) TW202220959A (hr)
UA (1) UA122433C2 (hr)
UY (1) UY37103A (hr)
WO (1) WO2017135306A1 (hr)
ZA (1) ZA201805544B (hr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3411358T1 (sl) 2016-02-04 2022-04-29 Takeda Pharmaceutical Company Limited Substituirana piperidinska spojina in njena uporaba
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
EP3663281B1 (en) * 2017-08-03 2022-12-28 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
IL300063B2 (en) 2017-08-03 2024-02-01 Takeda Pharmaceuticals Co Methanesulfonamide and its use for the prevention or treatment of narcolepsy
US11673867B2 (en) 2017-12-12 2023-06-13 University Of Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid-addition salt
EA039459B1 (ru) * 2017-12-25 2022-01-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение в качестве средства для лечения заболеваний, связанных с рецептором орексина 2 типа
JP7413261B2 (ja) * 2018-06-29 2024-01-15 武田薬品工業株式会社 複素環化合物およびその用途
US12077522B2 (en) 2018-06-29 2024-09-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
WO2020122092A1 (ja) 2018-12-12 2020-06-18 武田薬品工業株式会社 複素環化合物
JP7408569B2 (ja) * 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
US11028048B2 (en) * 2019-01-31 2021-06-08 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US12312332B2 (en) 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
AU2020346456A1 (en) * 2019-09-13 2022-04-14 Takeda Pharmaceutical Company Limited TAK-925 for use in treating narcolepsy
CA3154320A1 (en) * 2019-09-13 2021-03-18 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness
ES3041424T3 (en) * 2019-11-25 2025-11-12 Alkermes Inc Substituted macrocyclic compounds and related methods of treatment
MX2022006422A (es) 2019-11-27 2022-08-25 Sumitomo Pharma Co Ltd Derivado de cicloalquilurea.
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
EP4066893B1 (en) 2019-11-27 2025-07-30 Takeda Pharmaceutical Company Limited 6,7,8,9-tetrahydro-4h-quinolizin-4-one compound as orexin type 2 receptor agonist
MX2022008392A (es) * 2020-01-10 2022-08-08 Takeda Pharmaceuticals Co Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450.
CR20230089A (es) 2020-08-18 2023-04-11 Merck Sharp & Dohme Llc Agonistas de bicicloheptano pirrolidina de los receptores de orexina
WO2022040058A1 (en) * 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Cyclopentapyrrole orexin receptor agonists
JP2022064180A (ja) * 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US20240002397A1 (en) * 2020-11-23 2024-01-04 Merck Sharp & Dohme Llc 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2022190060A1 (en) 2021-03-12 2022-09-15 Takeda Pharmaceutical Company Limited An orexin 2 receptor agonist for the treatment of an orexin-mediated disease or disorder
TW202304437A (zh) 2021-04-02 2023-02-01 日商武田藥品工業股份有限公司 食慾激素２受體促效劑對於手術後復原的用途
CA3215210A1 (en) 2021-04-26 2022-11-03 Younggi Choi Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
US20240254143A1 (en) * 2021-05-03 2024-08-01 Jazz Pharmaceuticals Ireland Limited Orexin receptor agonists and uses thereof
BR112023024311A2 (pt) 2021-05-26 2024-02-06 Sumitomo Pharma Co Ltd Derivado de fenil ureia
EP4347604B1 (en) 2021-05-26 2025-12-03 Alkermes, Inc. Substituted carbamate macrocyclic compounds and related methods of treatment
CA3219506A1 (en) 2021-05-26 2022-12-01 Hoan Huynh Substituted fused bicyclic macrocyclic compounds and related methods of treatment
JP7668768B2 (ja) * 2021-05-26 2025-04-25 住友ファーマ株式会社 シクロアルキルウレア誘導体を含有する医薬組成物
US20250250230A1 (en) 2022-04-12 2025-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN119053606A (zh) 2022-04-22 2024-11-29 住友制药株式会社 双环胺甲酰胺衍生物
CN119730850A (zh) * 2022-06-21 2025-03-28 阿尔克姆斯有限公司 取代的稠合二环化合物以及相关的治疗方法
JP2025521507A (ja) * 2022-06-21 2025-07-10 アルカームス インコーポレーテッド 置換縮合二環式化合物および関連する治療方法
JP2025521503A (ja) * 2022-06-21 2025-07-10 アルカームス インコーポレーテッド 置換ピロリジニル及びピペリジニル化合物並びに関連する治療方法
JPWO2024075825A1 (hr) 2022-10-07 2024-04-11
TW202432109A (zh) 2022-10-31 2024-08-16 日商武田藥品工業股份有限公司 食慾素２型受體促效劑之給藥
AU2023375094A1 (en) 2022-10-31 2025-05-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2023403030A1 (en) 2022-11-30 2025-06-05 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP4635944A1 (en) 2022-12-16 2025-10-22 Daiichi Sankyo Company, Limited 2-azabicyclo[3.1.1]heptane compound
IL322817A (en) 2023-03-16 2025-10-01 Takeda Pharmaceuticals Co Macrocyclic heterocyclic compounds and their uses
WO2024246867A1 (en) 2023-06-02 2024-12-05 Takeda Pharmaceutical Company Limited Use of an orexin 2 receptor agonist for improving respiratory function during sleep
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2025211415A1 (ja) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 置換スルホンアミド化合物
WO2025211416A1 (ja) * 2024-04-04 2025-10-09 キッセイ薬品工業株式会社 置換スルホンアミド大環状化合物
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025229494A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229492A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Orexin type 2 receptor agonist microcapsules for sustained release dosing
WO2025229495A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608602A1 (fr) 1986-12-23 1988-06-24 Cerm Cent Europ Rech Mauvernay Nouvelles 3-piperidineamines ou 3-azepineamines substituees, leur preparation et leurs applications en therapeutique
SE9003652D0 (sv) 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds
ES2175083T3 (es) 1995-03-14 2002-11-16 Praecis Pharm Inc Moduladores de la agregacion de amiloides.
PT888353E (pt) 1996-03-15 2003-11-28 Novartis Ag Novas n-7-heterociclil-pirrolo¬2,3-d|pirimidinas e sua aplicacao
DK0929574T3 (da) 1996-08-27 2005-10-31 Praecis Pharm Inc Modulatorer af beta-amyloidpeptidaggregering, som omfatter D-aminosyrer
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
US6750344B1 (en) 1997-09-05 2004-06-15 Isis Pharmaceuticals, Inc. Amine compounds and combinatorial libraries comprising same
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
WO2001000663A2 (en) 1999-06-28 2001-01-04 Oklahoma Medical Research Foundation Catalytically active recombinant memapsin and methods of use thereof
AU6615300A (en) 1999-07-30 2001-02-19 Board Of Trustees Of The Leland Stanford Junior University Hypocretin and hypocretin receptors in regulation of sleep and related disorders
WO2001074162A1 (en) 2000-04-04 2001-10-11 The Regents Of The University Of California Treatment of sleep disorders with hypocretin-1
WO2004040000A2 (en) 2002-09-09 2004-05-13 Nura, Inc G protein coupled receptors and uses thereof
DK1572133T3 (da) 2002-12-13 2008-07-14 Janssen Pharmaceutica Nv Fremgangsmåde til identificering af modulatorer af den humane orexin-2-receptor
WO2009049215A1 (en) 2007-10-10 2009-04-16 Wake Forest University Health Sciences Methods to reduce the effects of sleep deprivation
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
US20130012493A1 (en) 2010-03-26 2013-01-10 He Zhao Novel spiro imidazolone derivatives as glucagon receptor antagonists, compositions, and methods for their use
JP5976011B2 (ja) * 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
US20140296288A1 (en) 2011-07-20 2014-10-02 Universite Pierre Et Marie Curie (Paris 6) Imino-sugar c-glycosides, preparation and use thereof
JP6484553B2 (ja) * 2012-07-03 2019-03-13 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ オレキシン受容体アンタゴニスト
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2015048091A1 (en) 2013-09-24 2015-04-02 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
WO2015088000A1 (ja) 2013-12-12 2015-06-18 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
KR101920472B1 (ko) 2014-03-06 2019-02-08 상하이 하이옌 파마슈티컬 테크놀로지 컴퍼니, 리미티드 오렉신 수용체 길항제로서의 피페리딘 유도체
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
EP3029024A1 (en) 2014-12-02 2016-06-08 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2016133160A1 (ja) 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
JP6189905B2 (ja) 2015-09-30 2017-08-30 株式会社スクウェア・エニックス ビデオゲーム処理プログラム、及びビデオゲーム処理システム
SI3411358T1 (sl) * 2016-02-04 2022-04-29 Takeda Pharmaceutical Company Limited Substituirana piperidinska spojina in njena uporaba

Also Published As

Publication number Publication date
AU2017215021B2 (en) 2020-07-23
KR102734774B1 (ko) 2024-11-26
US11292766B2 (en) 2022-04-05
PH12018501666B1 (en) 2023-05-26
EP3411358B1 (en) 2021-11-24
HRP20241334T1 (hr) 2025-01-03
JP6609060B2 (ja) 2019-11-20
US20220081399A1 (en) 2022-03-17
JP2019504098A (ja) 2019-02-14
IL260835A (en) 2019-02-28
AU2017215021A1 (en) 2018-08-30
TWI755374B (zh) 2022-02-21
LT3411358T (lt) 2022-04-25
WO2017135306A1 (en) 2017-08-10
HUE057696T2 (hu) 2022-05-28
US20240174610A1 (en) 2024-05-30
ES2907373T3 (es) 2022-04-25
CA3013428C (en) 2024-02-13
CA3013428A1 (en) 2017-08-10
NZ745259A (en) 2025-03-28
SI3411358T1 (sl) 2022-04-29
CL2018002099A1 (es) 2018-11-09
BR112018015574A2 (pt) 2018-12-26
MA43963A (fr) 2018-12-12
PL3411358T3 (pl) 2022-02-28
AR107519A1 (es) 2018-05-09
TW202220959A (zh) 2022-06-01
EA036166B1 (ru) 2020-10-08
US10287305B2 (en) 2019-05-14
PL3984994T3 (pl) 2024-11-04
LT3984994T (lt) 2024-10-10
EP3411358A1 (en) 2018-12-12
HUE068362T2 (hu) 2024-12-28
EA201891742A1 (ru) 2019-01-31
CO2018008705A2 (es) 2018-11-13
SI3984994T1 (sl) 2024-12-31
EP3984994B1 (en) 2024-07-03
FI3984994T3 (fi) 2024-10-03
EP4438041A2 (en) 2024-10-02
RS62861B1 (sr) 2022-02-28
CN114181136A (zh) 2022-03-15
ZA201805544B (en) 2019-11-27
CN108884043B (zh) 2021-11-26
UA122433C2 (uk) 2020-11-10
TW201731817A (zh) 2017-09-16
TN2018000262A1 (en) 2020-01-16
US10508083B2 (en) 2019-12-17
ECSP18066504A (es) 2018-10-31
US20190031611A1 (en) 2019-01-31
SG11201806429PA (en) 2018-08-30
US10898737B2 (en) 2021-01-26
MX2018009494A (es) 2018-09-06
MY186905A (en) 2021-08-26
DK3411358T3 (da) 2022-01-17
US20170226137A1 (en) 2017-08-10
PT3984994T (pt) 2024-10-10
KR20180103985A (ko) 2018-09-19
ES2991028T3 (es) 2024-12-02
MX382435B (es) 2025-03-13
RS65984B1 (sr) 2024-10-31
US20190263843A1 (en) 2019-08-29
US12281073B2 (en) 2025-04-22
EP4438041A3 (en) 2025-01-01
PH12018501666A1 (en) 2019-06-17
PT3411358T (pt) 2022-01-19
UY37103A (es) 2017-08-31
BR112018015574B1 (pt) 2023-11-28
EP3984994A1 (en) 2022-04-20
CY1125003T1 (el) 2023-01-05
DK3984994T3 (da) 2024-10-14
CN108884043A (zh) 2018-11-23
US20200115399A1 (en) 2020-04-16
IL260835B (en) 2021-10-31

Similar Documents

Publication Publication Date Title
HRP20220127T1 (hr) Supstituirani spoj piperidina i njegova uporaba
JP2019504098A5 (hr)
HRP20190947T1 (hr) Heterociklički spoj
AR081072A1 (es) Derivados de 3,3-dimetil-tetrahidroquinolina, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos para el tratamiento de la diabetes, obesidad y dislipemia
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
CY1122272T1 (el) ΕΝΩΣΕΙΣ 3-ΚΥΚΛΟΕΞΕΝΥΛ ΚΑΙ ΚΥΚΛΟΕΞΥΛ ΥΠΟΚΑΤΕΣΤΗΜΕΝΟΥ ΙΝΔΟΛΙΟΥ ΚΑΙ ΙΝΔΑΖΟΛΙΟΥ ΩΣ RORgammaT ΑΝΑΣΤΟΛΕΙΣ ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
ES2531274T3 (es) Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
HRP20191579T1 (hr) Spojevi kao modulatori za ror gama
PE20130306A1 (es) Morfolinopirimidinas y su uso en terapia
BR112014027143A2 (pt) pirrolobenzodiazepinas
PE20161427A1 (es) Inhibidores heteroarilo de syk
NZ603643A (en) Purinone derivative
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
PE20142186A1 (es) Derivados biciclicos de pirazinona
AR086198A1 (es) Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen
PE20121815A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
PE20141974A1 (es) Compuestos de heterociclilo
PE20140502A1 (es) Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas
PE20160751A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
CO6220966A2 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa
PE20161443A1 (es) Compuestos
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
ES2722409T3 (es) Moduladores de ROR gamma (RORy)
PH12013501754A1 (en) Triazolopyridine compounds as pim kinase inhibitors